Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, 3700 Hamilton Walk, Philadelphia, PA 19104, USA.
Penn Memory Center, Department of Neurology, 3700 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104, USA.
Neuroimage Clin. 2018 Feb 8;18:407-412. doi: 10.1016/j.nicl.2018.02.008. eCollection 2018.
Suspected non-Alzheimer's pathophysiology (SNAP) is a biomarker driven designation that represents a heterogeneous group in terms of etiology and prognosis. SNAP has only been identified by cross-sectional neurodegeneration measures, whereas longitudinal measures might better reflect "active" neurodegeneration and might be more tightly linked to prognosis. We compare neurodegeneration defined by cross-sectional 'hippocampal volume' only (SNAP/L-) versus both cross-sectional and longitudinal 'hippocampal atrophy rate' (SNAP/L+) and investigate how these definitions impact prevalence and the clinical and biomarker profile of SNAP in Mild Cognitive Impairment (MCI).
276 MCI patients from ADNI-GO/2 were designated amyloid "positive" (A+) or "negative" (A-) based on their florbetapir scan and neurodegeneration 'positive' or 'negative' based on cross-sectional hippocampal volume and longitudinal hippocampal atrophy rate.
74.1% of all SNAP participants defined by the cross-sectional definition of neurodegeneration also met the longitudinal definition of neurodegeneration, whereas 25.9% did not. SNAP/L+ displayed larger white matter hyperintensity volume, a higher conversion rate to dementia over 5 years and a steeper decline on cognitive tasks compared to SNAP/L- and the A- CN group. SNAP/L- had more abnormal values on neuroimaging markers and worse performance on cognitive tasks than the A- CN group, but did not show a difference in dementia conversion rate or longitudinal cognition.
Using a longitudinal definition of neurodegeneration in addition to a cross-sectional one identifies SNAP participants with significant cognitive decline and a worse clinical prognosis for which cerebrovascular disease may be an important driver.
疑似非阿尔茨海默病病理生理学(SNAP)是一种基于生物标志物的诊断,代表了一组病因和预后不同的异质性群体。SNAP 仅通过横断面神经退行性改变来识别,而纵向测量可能更好地反映“活跃”的神经退行性改变,并且可能与预后更紧密相关。我们比较了仅通过横断面“海马体积”定义的神经退行性改变(SNAP/L-)与同时通过横断面和纵向“海马萎缩率”定义的神经退行性改变(SNAP/L+),并探讨了这些定义如何影响轻度认知障碍(MCI)中 SNAP 的患病率以及 SNAP 的临床和生物标志物特征。
根据他们的 florbetapir 扫描,ADNI-GO/2 中的 276 名 MCI 患者被指定为淀粉样蛋白“阳性”(A+)或“阴性”(A-),根据横断面海马体积和纵向海马萎缩率将神经退行性改变指定为“阳性”或“阴性”。
所有通过横断面神经退行性改变定义的 SNAP 参与者中,有 74.1%也符合纵向神经退行性改变的定义,而 25.9%不符合。与 SNAP/L-和 A- CN 组相比,SNAP/L+显示出更大的白质高信号体积、5 年内向痴呆转化的更高转化率以及认知任务上更陡峭的下降。与 A- CN 组相比,SNAP/L-的神经影像学标志物异常值更多,认知任务表现更差,但痴呆转化率或纵向认知无差异。
除了横断面定义外,使用纵向定义的神经退行性改变可以识别出具有显著认知下降和更差临床预后的 SNAP 参与者,其中血管性疾病可能是一个重要的驱动因素。